USFDA excludes Ceftriazone Sodium from import alert: Wockhardt

By: | Published: October 3, 2016 10:30 PM

Drug firm Wockhardt today said the US health regulator has excluded Ceftriazone Sodium from import alert issued earlier against its active pharmaceutical ingredient manufacturing facility at Ankleshwar.

wockhardt sharesDrug firm Wockhardt today said the US health regulator has excluded Ceftriazone Sodium from import alert issued earlier against its active pharmaceutical ingredient manufacturing facility at Ankleshwar. (Reuters)

Drug firm Wockhardt today said the US health regulator has excluded Ceftriazone Sodium from import alert issued earlier against its active pharmaceutical ingredient manufacturing facility at Ankleshwar.

The United States Food and Drug Administration (USFDA) on September 30, 2016 has posted on its website an update on the Import Alert 66-40 “regarding company’s API Unit at Ankleshwar” and excluded Ceftriazone Sodium from it, Wockhardt said in a filing to BSE.

“This will enable the company to manufacture and sell Ceftriazone API and formulation to US market,” it added.

Shares of Wockhardt today closed at Rs 894.45 per scrip on BSE, up 1.86 per cent from its previous close.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Switch to Hindi Edition